2.07
0.05 (2.48%)
Penutupan Terdahulu | 2.02 |
Buka | 2.03 |
Jumlah Dagangan | 1,585,199 |
Purata Dagangan (3B) | 696,921 |
Modal Pasaran | 88,707,160 |
Harga / Pendapatan (P/E TTM) | 0.506 |
Harga / Jualan (P/S) | 13.27 |
Julat 52 Minggu | |
Tarikh Pendapatan | 14 Aug 2025 |
EPS Cair (TTM) | 4.09 |
Nisbah Semasa (MRQ) | 0.720 |
Aliran Tunai Operasi (OCF TTM) | -64.05 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -35.91 M |
Pulangan Atas Aset (ROA TTM) | -122.34% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Menurun |
Biotechnology (Global) | Bercampur | Menurun | |
Stok | Outlook Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | 3.5 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | 5.0 |
Osilator Teknikal | 5.0 |
Purata | 2.88 |
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 38.31% |
% Dimiliki oleh Institusi | 16.81% |
Julat 52 Minggu | ||
Median | 21.00 (914.49%) | |
Jumlah | 1 Beli |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Ascendiant Capital | 06 Jun 2025 | 21.00 (914.49%) | Beli | 1.90 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |